Micardis®. Observational Study in Patients With Essential Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Low dose of Telmisartan, once daily (Drug); High dose of Telmisartan, once daily (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
This study is designed to supplement, under conditions of usual clinical practice, the data
on the efficacy and safety of Micardis® collected during the clinical studies.
Clinical Details
Official title: Micardis®. Observational Study
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Changes in systolic and diastolic blood pressurePercentage of patients with dose titration to 80 mg Number of patients with adverse events Global evaluation of treatment compliance by investigator, a 6-point rating scale
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients of either sex over the age of 18 years suffering from essential hypertension
requiring treatment according to the physician
Exclusion Criteria:
- Hypersensitivity to the active component or to any of the excipients
- Pregnancy and lactation
- Biliary obstructive disorders
- Severe hepatic impairment
- Severe renal impairment
Locations and Contacts
Additional Information
Starting date: December 1999
Last updated: July 24, 2014
|
